# Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

> **NCT04986202** · PHASE2,PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 711 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** AZD4831
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04986202
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-30
- **Primary completion:** 2024-03-27
- **Final completion:** 2024-03-27
- **Target enrollment:** 711 (ACTUAL)
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04986202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04986202, "Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04986202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*